AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01037504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
Study NCT01037504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
Study NCT00660478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor
Description: Comparison of two different drug eluting coronary stents
Study NCT00660478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher Select
Description: Comparison of two different drug eluting coronary stents
Study NCT04761237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDET)
Description: Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
Study NCT01955694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
Study NCT01955694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
Study NCT01955694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study NCT01955694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT02876471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPAP
Description: OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
Study NCT02886741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality Improvement Campaign
Description: How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty.
Study NCT00494442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral
Study NCT00923676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: pill 145 mg, 145 mg/day, for 12 months
Study NCT00923676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: pills of 10 mg, 10 mg/day, 12 months
Study NCT00923676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate + rosuvastatin
Description: fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
Study NCT05242926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
Study NCT04299360 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy device programming
Description: Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
Study NCT03949686 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution
Description: 0.5 ml/kg saline
Study NCT03949686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg %0.25 bupivacaine
Study NCT03034915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg via ELLIPTA
Description: ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
Study NCT03034915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 mcg via ELLIPTA
Description: The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
Study NCT03034915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 mcg via DISKUS
Description: The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Study NCT03034915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via ELLIPTA
Description: Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
Study NCT03034915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via DISKUS
Description: Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
Study NCT03369587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwriting Practice
Description: Self-directed home handwriting practice daily for 6 weeks
Study NCT03369587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handwriting Practice
Description: Self-directed home handwriting practice daily for 6 weeks
Study NCT01228851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Group balance training sessions three times a week for 8 weeks
Study NCT01982643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone plus bupropion
Description: Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
Study NCT03898986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV4)
Description: LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
Study NCT03898986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV4)
Description: IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
Study NCT01168011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
Study NCT03321539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT+GP
Description: Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
Study NCT03321539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCRT+PF
Description: Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
Study NCT05097573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
Study NCT00944801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicine
Description: In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
Study NCT04333069 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: cataract surgery in form of phaco emulsification or irrigation aspiration
Study NCT04604054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulated Factor
Description: GCSF was intrauterine injected once at ovum pick up day
Study NCT04604054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropins
Description: 500 IU of HCG was injected intrauterine once at ovum pick up day
Study NCT02888431 — intervention group
Intervention type: DEVICE
Intervention: bedside point-of-care device
Description: A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
Study NCT05098340 — intervention group
Intervention type: GENETIC
Intervention: Quantitative Real-time polymerase chain reaction
Description: Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
Study NCT02534441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin patch test
Study NCT02678104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth removal
Study NCT02678104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth wash
Description: Chlorhexidine mouth wash
Study NCT02678104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-alveolar application of Manuka Honey
Description: Intra-alveolar application of Manuka Honey directly after extraction.
Study NCT01947179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Risk Reduction
Description: Involves psychoeducation and interoceptive exposure exercises
Study NCT01064024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine Hydrochloride
Description: Tablets, 200 mg, every 8 hours for 48 hours.
Study NCT01064024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, every 8 hours for 48 hours
Study NCT01652248 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac resynchronisation therapy
Description: Upgrade to CRT at the time of generator replacement
Study NCT01652248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronisation therapy
Description: Upgrade to CRT at the time of generator replacement
Study NCT01239186 — intervention group
Intervention type: OTHER
Intervention: methylation analyses on spermatozoa from infertile men
Description: microarray analysis(www.EPIGENOMICS.com)
Study NCT02446730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BES (biodegradable polymer biolimus-eluting stent)
Description: BES implantation
Study NCT02446730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugel
Study NCT02446730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT04601142 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
Study NCT00294008 — intervention group
Intervention type: DRUG
Intervention: Risperdal Consta
Description: flexible dosage for 24 months
Study NCT01094002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Description: Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities.
Study NCT02383784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High GI diet
Description: High glycemic index diet
Study NCT00674102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Study NCT00649584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35
Description: IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
Study NCT00649584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: IV; 1000 mg/m2 weekly 3 out of 4 weeks
Study NCT03090152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular injection (Deep injection)
Description: Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata.
Study NCT03090152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular injection (Deep injection)
Description: Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata.
Study NCT03090152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periarticular injection (Superficial injection)
Description: Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
Study NCT03090152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular injection (Superficial injection)
Description: Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
Study NCT03090152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: EPCA: Bupivacaine 0.06%.
Study NCT03090152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: EPCA: Bupivacaine 0.06%.
Study NCT03090152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: EPCA: Saline.
Study NCT00853853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EnSeal Device
Description: Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
Study NCT00853853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ferguson Hemorrhoidectomy technique
Description: The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
Study NCT04701554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong program
Description: The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
Study NCT04701554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information on healthy lifestyles, physical exercise and dietary recommendations.
Description: The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
Study NCT02048007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Biannual mass oral azithromycin to children
Study NCT02048007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Biannual mass oral placebo to children
Study NCT03283241 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Zolidd One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.
Study NCT03283241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zolidd One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.
Study NCT03283241 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.
Study NCT03283241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One ExHex
Description: Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24.
Study NCT03637348 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TrueTear
Description: Ues of TrueTear neurostimulator
Study NCT00629928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg oral capsule daily
Study NCT00629928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral capsule daily
Study NCT00629928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02378480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Injection for IV dosing; Tablets for oral dosing
Study NCT02378480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Infusion solution for IV dosing; Tablets for oral dosing
Study NCT03205267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosulif
Description: Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
Study NCT01230060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista
Description: One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
Study NCT03855904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-325
Description: TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.